IGF1R and Miyoshi myopathy: Moreover, we investigated the impact of CRISPR-Cas9-mediated IGF1R knockout on the proliferation in the IGF1R-mutant HMCL L-363 and the IGF1R wild-type (WT) HMCL U-266 and analyzed the response to IGF1R inhibition in seven HMCLs using linsitinib in combination with the second-generation PI carfilzomib, commonly used in relapsed refractory MM [44].